Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

JNJJanssen Research & Development, LLCFinished

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 4 insiders sold shares within a month

    Since Aug 17, 2026 · was worth 5, fading over time

    +2
Worry score2

Score over time

Stage
Phase 3
Patients
390 (final count)
Started
Nov 7, 2017
Main results expected
May 1, 2024
Fully finished
May 4, 2026
Results posted
Dec 23, 2025

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

    Measured over: From randomization (Day -5) up to 77 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT03301220 · record last updated 2026-06-08 · checked 2026-11-09 15:42 UTC

See the official record on ClinicalTrials.gov (NCT03301220) ↗